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ABSTRACT 
 
Malaria is one of the most important tropical diseases, with hundreds of millions 
of cases every year. The current recommended treatment is an artemisinin based 
combination therapy (ACT), which has shown good efficacy. However, 
differences in exposure have been observed in children and pregnant women for 
some antimalarial drugs. Interactions might also change the outcome of the 
treatment. Recently resistance development has been noted, which further 
underlines the importance to optimise these treatments. In this thesis, a nonlinear 
mixed-effects modelling approach has been used to optimise the treatment with 
ACT. The aims were to optimise the treatment with piperaquine, and to investigate 
the interactions between the antimalarial drug combination artemether-
lumefantrine and antiretroviral therapy. The pharmacokinetics of piperaquine 
during pregnancy was investigated, and no difference in exposure was found. 
However, a difference in exposure was found in children, and a new optimised 
dose regimen for children and adults were derived. A significant difference in 
clinical outcome was found between three sites in Cambodia.  Potential 
interactions between antimalarials and antiretrovirals were investigated and a 
significant difference in the exposure of lumefantrine was found when combined 
with the three antiretroviral drugs efavirenz, nevirapine or lopinavir, and new 
doses for artemether-lumefantrine were simulated. Exposure of nevirapine was 
also found to differ when combined with artemether-lumefantrine, and a new dose 
suggestion was simulated. In conclusion, this thesis has optimised the treatment of 
piperaquine and the co-treatment of artemether-lumefantrine and efavirenz, 
nevirapine and ritonavir boosted lopinavir. 
 
Keywords: Malaria, pharmacometrics, HIV, drug-drug interactions, pediatrics, pregnancy,  
dose optimisation 
 
ISBN: 978-91-628-9240-1 
